Bayer's investigational drug Riociguat granted FDA orphan drug designation: NAPSR News

Bayer HealthCare today announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development has granted two separate orphan drug designations for its investigational, oral medication riociguat



via Education - Latest News http://www.prlog.org/12217524-bayers-investigational-drug-riociguat-granted-fda-orphan-drug-designation-napsr-news.html